IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, and CareFusion (NYSE: CFN), a leading global medical device company, today announced a multi-year technology licensing agreement establishing the breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology to be used in CareFusion infusion and respiratory products under development*.
Incorporating Masimo Rainbow SET Pulse CO-Oximetry technology will enable CareFusion's future infusion and respiratory products (under development*) to noninvasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise. The ability to automatically assess total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI® for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate directly from CareFusion's ventilators and infusion pumps may facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions.
Currently, CareFusion uses Masimo technology in the Alaris® SpO2 module to help safeguard PCA delivery through the Alaris® System. The Alaris® PCA module together with the Alaris® SpO2 module--featuring Masimo SET® pulse oximetry technology for accurate and trustworthy measure-through motion and low-perfusion SpO2, pulse rate, and perfusion index measurements--provides an additional safety net for risk factors not covered by programming safety and bar coding, such as previously undiagnosed clinical conditions and PCA by proxy. The system offers the clinician the unique ability to automatically pause PCA infusion if a patient falls below hospital-defined respiratory monitoring limits.
"Masimo is a great partner with excellent technology," said Gordon LaFortune, senior vice president and general manager of Infusion Systems for CareFusion. "We're happy to be working with them to incorporate their technology in our products."
Masimo President of OEM Business, Rick Fishel stated, "We look forward to a growing technology partnership with CareFusion and the possibilities created by the integration of Masimo Rainbow SET into CareFusion's infusion and respiratory products."
*Future vision: As of the date of the communication, the products under development have not been cleared for commercial sale by the FDA. The products under development may not be cleared for commercial sale by the FDA. The company may not make the products under development available for commercial sale.
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET® Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to the timing, commercial availability, and regulatory clearance of CareFusion infusion and respiratory products under development that may or may not incorporate Masimo Rainbow SET, risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that the noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET may facilitate earlier detection, diagnosis, and treatment of potentially life-threatening conditions to increase patient safety, improve the quality of care, and reduce the cost of care, risks related to our belief that Masimo SET will deliver sufficient sensitivity and specificity to deliver the most accurate and reliable measurements under all conditions of patient motion and low peripheral perfusion, and risks related to our assumption that Masimo SET will help improve the regulation and delivery of oxygen therapy to neonates, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Media Contacts: Dana Banks Masimo Corporation +1 (949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Copyright©2009 PR Newswire.
All rights reserved